Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis

NCT00326508 is registered in ClinicalTrials.gov with National Eye Institute (NEI) as lead sponsor.

NCT NCT00326508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis
Lead sponsor
National Eye Institute (NEI)
Phase
Phase 2
Overall status
Completed
Start date
May 11, 2006
Completion date
December 20, 2006
Enrollment
5
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-infectious intermediate and posterior uveitis